Straits Times Index
3,336.59 +13.21 (+0.40%) S&P 500
5,277.51 +42.03 (+0.80%) Dow
38,686.32 +574.82 (+1.51%) Nasdaq
16,735.02 -2.08 (-0.01%) Bitcoin USD
67,624.74 -46.92 (-0.07%) CMC Crypto 200
1,462.76 +34.19 (+2.39%)
LRMR Nov 2024 10.000 call
| Previous close | 0.7900 |
| Open | 0.7900 |
| Bid | 0.9000 |
| Ask | 2.3500 |
| Strike | 10.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.7900 - 0.7900 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswireLarimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseasesNomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease and demonstrated development program readinessSTART pilot program is intended to improve development efficiency through enhanced communication with the FDANomlabofusp is expected to be one of three CDER programs and one of six total programs sele
- GlobeNewswire
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension (OLE) study initially evaluating 25 mg; Larimar plans to dose escalate to 50 mg following further characterization of frataxin pharmacodynamics (PD) at the 25 mg doseInterim data from OLE study remains on track for Q4 2024Biologics License Application (BLA) submission targeted for 2H 2025 BALA CYNWYD, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Larimar T
Simply Wall St.Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
